Allurion Technologies Inc. (ALUR)
NYSE: ALUR · Real-Time Price · USD
0.704
-0.037 (-4.94%)
Nov 7, 2024, 4:00 PM EST - Market closed
Company Description
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight.
Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.
Allurion Technologies Inc. is headquartered in Natick, Massachusetts.
Allurion Technologies Inc.
Country | United States |
Founded | 2009 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 504 |
CEO | Shantanu Gaur |
Contact Details
Address: 11 Huron Drive Natick, Massachusetts 01760 United States | |
Phone | 508 647 4000 |
Website | allurion.com |
Stock Details
Ticker Symbol | ALUR |
Exchange | NYSE |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001964979 |
CUSIP Number | 02008G102 |
ISIN Number | US02008G1022 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Dr. Shantanu K. Gaur M.D. | Co-Founder, Chief Executive Officer, President and Director |
Christopher Geberth | Chief Financial Officer and Treasurer |
Dr. Samuel G. Levy | Co-Founder |
Dr. Ram Chuttani M.D. | MD, Chief Medical Officer and Founding Partner |
Ojas A. Buch | Chief Operating Officer |
Brendan Michael Gibbons | Chief Legal Officer and Corporate Secretary |
Matt Wright | Vice President of People |
Joyce Johnson | Senior Vice President of Regulatory Affairs and Quality Assurance |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 5, 2024 | 424B3 | Prospectus |
Nov 5, 2024 | 424B3 | Prospectus |
Nov 5, 2024 | 424B3 | Prospectus |
Nov 4, 2024 | 8-K | Current Report |
Oct 29, 2024 | 424B3 | Prospectus |
Oct 29, 2024 | 424B3 | Prospectus |
Oct 29, 2024 | 424B3 | Prospectus |
Oct 29, 2024 | 424B3 | Prospectus |
Oct 28, 2024 | 8-K | Current Report |
Oct 28, 2024 | PRE 14A | Other preliminary proxy statements |